Phosphorus in the Blood: High and Low Results, Causes and Next Steps

The phosphorus concentration in the blood depends on three processes: absorption in the gut, exchange with bone and cells, and excretion by the kidneys. In a healthy body the kidneys play the decisive role: the proximal tubules reabsorb phosphate from the filtrate, and hormones regulate how much of it returns to the blood. Parathyroid hormone (PTH) increases phosphate excretion in urine (while raising calcium), and the phosphatonin FGF23, produced mainly in bone, does the same and in addition suppresses the formation of active vitamin D. Active vitamin D (calcitriol), in turn, increases the absorption of both calcium and phosphorus in the gut.

A review published in 2024 in Best Practice & Research Clinical Endocrinology & Metabolism stresses that once FGF23 was identified as the pivotal regulator of chronic phosphorus levels, the etiology of disorders leading to rickets and osteomalacia with hypophosphatemia could be organized, and measurement of FGF23 serves as a valuable tool for the differential diagnosis of chronic hypophosphatemia. The authors divide the causes of chronic hypophosphatemia into four groups: FGF23-related, primary renal tubular disorders, disturbances of vitamin D metabolism, and PTH1R-mediated. Measurement of bone-specific alkaline phosphatase helps distinguish acute and subacute hypophosphatemia from chronic.

Phosphorus is one of those parameters that are easy to 'read' too literally. First, its concentration fluctuates during the day (usually lower in the morning and higher in the evening) and changes after a meal, especially one with a lot of carbohydrate, because insulin shifts phosphorus into cells. Second, the result is raised by hemolysis of the sample, and some measurement methods give falsely high values in paraproteinemia (for example in monoclonal gammopathy), with very high lipids or with bilirubin. Third, reference ranges depend on age: in children and adolescents the range is higher because of bone growth, so the same concentration that is normal in a child would be raised in an adult.

An important, counterintuitive message follows for the reader: in people with healthy kidneys, how much phosphorus you eat has little effect on the blood result, and what you see in the test reflects hormonal regulation and kidney function. That is why changing the diet rarely 'fixes' an abnormal phosphorus outside kidney disease, and avoiding dairy, meat or nuts on your own 'to lower phosphorus' has no justification in a person without chronic kidney disease. The exception is phosphate additives in processed food, which are absorbed far better than phosphorus occurring naturally in plants and matter mainly in advanced kidney disease.

If high phosphorus is not an artifact, it almost always means that the kidneys cannot keep up with excreting it. In chronic kidney disease, phosphate excretion falls as glomerular filtration declines, and the body initially compensates with rising FGF23 and PTH. Only when the compensatory mechanisms fail (usually at an eGFR below about 30–40 ml/min/1.73 m²) does blood phosphorus start to rise. Hyperphosphatemia is therefore usually a late sign of kidney disease and one of the elements of the mineral and bone disorder of chronic kidney disease (CKD-MBD).

This result, although from the 1990s and concerning only dialysis patients, shaped thinking about phosphorus in nephrology. The 2017 update of the KDIGO guidelines on CKD-MBD includes treatment aimed at lowering phosphate and maintaining calcium, together with management of PTH abnormalities and bone disorders. It is fair, however, to note that the evidence that simply lowering phosphorus with drugs (phosphate binders) improves hard endpoints is weaker than the observational evidence: in the randomized LANDMARK trial, covering 2,309 hemodialysis patients, comparing lanthanum carbonate with calcium carbonate showed no significant difference in cardiovascular events.

Hypophosphatemia is common in hospitalized patients and in severe illness, but it also occurs in healthy people in specific situations. The mechanisms can be divided into three groups: a shift of phosphorus into cells (after insulin and glucose, with hyperventilation and respiratory alkalosis, in refeeding syndrome, in 'hungry bone' syndrome after parathyroid surgery), reduced intake or absorption (malnutrition, malabsorption, vitamin D deficiency, long-term use of antacids containing aluminum or magnesium, which bind phosphate in the gut), and increased loss through the kidneys (hyperparathyroidism, excess FGF23, Fanconi syndrome, alcoholism, some drugs and tumors).

One of the more interesting and relatively recently described causes is the intravenous administration of some iron preparations. Some forms (especially ferric carboxymaltose) stimulate FGF23, which causes urinary phosphorus loss and hypophosphatemia. The scale of the phenomenon was shown by a comparison of two preparations in randomized trials.

The practical conclusion for the patient is this: if fatigue, bone pain or muscle weakness appear after an iron infusion and phosphorus is low, the result should be discussed with the treating doctor, along with the type of iron preparation for future courses. Hypophosphatemia after iron is usually transient, but in selected people (especially after repeated infusions) it can be chronic and lead to osteomalacia, so it should not be dismissed.

For readers interested in fasting, very-low-calorie diets and biohacking, refeeding syndrome is particularly relevant. After a longer period of calorie deficit the body has depleted intracellular stores of phosphorus, potassium and magnesium. When abundant feeding begins again, the rise in insulin shifts these electrolytes into cells and blood phosphorus falls sharply. Severe hypophosphatemia can lead to weakness of the respiratory muscles, heart failure, rhythm disturbances and even seizures.

A 2021 meta-analysis covering 35 observational studies shows how much the frequency of the syndrome depends on the definition adopted and the population: the proportion with refeeding syndrome ranged from 0% to 62%, and with refeeding hypophosphatemia from 7% to 62%, with events more frequent in intensive care units and with a higher initial calorie supply (above 20 kcal/kg/day). The authors stress the absence of a generally accepted definition, so the percentage values themselves should be interpreted with caution.

Mild deviations in phosphorus usually cause no symptoms, and when symptoms are present they stem more from the underlying disease than from the concentration itself. Chronically high phosphorus in kidney disease can cause itching of the skin, bone and joint pain and, in the longer term, calcification of vessels and soft tissues, because phosphates combine with calcium and deposit in tissues. A sudden, large rise in phosphorus (for example in tumor lysis) can sharply lower calcium and cause numbness, muscle cramps, rhythm disturbances and seizures.

Low phosphorus of mild degree is usually asymptomatic. In moderate and severe degree (in many sources below about 1.0 mg/dl, i.e. 0.32 mmol/l) there is muscle weakness, fatigue, bone pain and, in extreme cases, respiratory failure, heart failure, muscle breakdown (rhabdomyolysis), hemolytic anemia and neurological disturbances. Chronic hypophosphatemia in children leads to rickets, and in adults to osteomalacia, i.e. softening of bones, with bone pain and fractures after minor injury.

Phosphorus is not interpreted in isolation from other parameters. The set of tests is chosen depending on whether the result is high or low and on the history. The list below shows what you can expect.

Phosphorus is always interpreted together with calcium and PTH. When phosphorus is high, calcium low and PTH high, we speak of secondary hyperparathyroidism in kidney disease; when phosphorus is low, calcium high and PTH high, this is the picture typical of primary hyperparathyroidism (which we describe in the article on high calcium). When phosphorus is low and calcium and PTH are normal, we look for vitamin D deficiency, refeeding syndrome, alcohol or drugs.

In people with normal kidney function there is no justification for restricting dietary phosphorus or for supplementing it on your own. Phosphorus occurs in dairy, meat, fish, eggs, legumes, nuts and whole grains, and healthy kidneys cope easily with any excess. The exception is patients with chronic kidney disease, whose dietary advice is set by a nephrologist or clinical dietitian: limiting phosphate additives (in cola-type drinks, cured meats, processed cheese and 'convenience' foods), choosing foods with a favorable phosphorus-to-protein ratio and, where needed, phosphate binders taken with meals.

With low phosphorus, treatment depends on the cause. In mild hypophosphatemia removing the cause is usually enough (for example stopping a drug, replenishing vitamin D, a balanced diet); in more severe cases the doctor orders oral or intravenous phosphate preparations under monitoring of levels. Taking phosphates on your own without a diagnosis can be risky, because excess may lower calcium and burden the kidneys. In refeeding syndrome, treatment requires monitoring in hospital.

Phosphorus is a parameter that rarely arouses interest and can be remarkably instructive. A high result prompts a check of the kidneys and parathyroids; a low one, a question about recent fasting, alcohol, drugs and vitamin D deficiency. In both cases the value makes sense only alongside calcium, PTH and creatinine. The best advice is a patient, orderly approach: repeat the test, take a history and order a few supplementary tests, rather than changing diet or reaching for a supplement.

For people who practice long fasts or very-low-calorie diets, we recommend careful, gradual re-entry from a fast and, if BMI is low or there have been earlier complications, consultation before starting. And people after an iron infusion with persistent muscle and bone complaints should ask for phosphorus to be checked; it is a simple, cheap analysis that can explain surprising symptoms.